Source: Pharmacy Times articles
An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.
by MM360 Staff | Sep 18, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.